390 related articles for article (PubMed ID: 10589779)
41. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
[TBL] [Abstract][Full Text] [Related]
42. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma.
Kushner BH; Kramer K; Modak S; Qin LX; Cheung NK
Cancer; 2010 Jun; 116(12):3054-60. PubMed ID: 20564411
[TBL] [Abstract][Full Text] [Related]
43. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Mirchandani D; Hochster H; Hamilton A; Liebes L; Yee H; Curtin JP; Lee S; Sorich J; Dellenbaugh C; Muggia FM
Clin Cancer Res; 2005 Aug; 11(16):5912-9. PubMed ID: 16115933
[TBL] [Abstract][Full Text] [Related]
44. Melphalan: a potential new agent in the treatment of childhood rhabdomyosarcoma.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Cancer Treat Rep; 1985 Jan; 69(1):91-6. PubMed ID: 3967262
[TBL] [Abstract][Full Text] [Related]
45. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.
Daw NC; Santana VM; Iacono LC; Furman WL; Hawkins DR; Houghton PJ; Panetta JC; Gajjar AJ; Stewart CF
J Clin Oncol; 2004 Mar; 22(5):829-37. PubMed ID: 14990638
[TBL] [Abstract][Full Text] [Related]
48. Scheduling of vincristine: drug accumulation and response of xenografts of childhood rhabdomyosarcoma determined by frequency of administration.
Houghton JA; Meyer WH; Houghton PJ
Cancer Treat Rep; 1987; 71(7-8):717-21. PubMed ID: 3607783
[TBL] [Abstract][Full Text] [Related]
49. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
50. Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach.
Santana VM; Furman WL; Billups CA; Hoffer F; Davidoff AM; Houghton PJ; Stewart CF
J Clin Oncol; 2005 Jun; 23(18):4039-47. PubMed ID: 15961757
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group.
Frangoul H; Ames MM; Mosher RB; Reid JM; Krailo MD; Seibel NL; Shaw DW; Steinherz PG; Whitlock JA; Holcenberg JS
Clin Cancer Res; 1999 Dec; 5(12):3956-62. PubMed ID: 10632325
[TBL] [Abstract][Full Text] [Related]
52. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
Panetta JC; Schaiquevich P; Santana VM; Stewart CF
Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton JA; Houghton PJ; Green AA
Cancer Res; 1982 Feb; 42(2):535-9. PubMed ID: 7034923
[TBL] [Abstract][Full Text] [Related]
54. Topotecan-based combination chemotherapy for human malignant glioma.
Schmidt F; Schuster M; Streffer J; Schabet M; Weller M
Anticancer Res; 1999; 19(2A):1217-21. PubMed ID: 10368678
[TBL] [Abstract][Full Text] [Related]
55. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
Balsari A; Tortoreto M; Besusso D; Petrangolini G; Sfondrini L; Maggi R; Ménard S; Pratesi G
Eur J Cancer; 2004 May; 40(8):1275-81. PubMed ID: 15110894
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic efficacy of the cyclopropylpyrroloindole, carzelesin, against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Hallman JD; Houghton JA
Cancer Chemother Pharmacol; 1995; 36(1):45-52. PubMed ID: 7720175
[TBL] [Abstract][Full Text] [Related]
57. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
58. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model.
Kaiser MG; Parsa AT; Fine RL; Hall JS; Chakrabarti I; Bruce JN
Neurosurgery; 2000 Dec; 47(6):1391-8; discussion 1398-9. PubMed ID: 11126910
[TBL] [Abstract][Full Text] [Related]
59. The pediatric preclinical testing program: description of models and early testing results.
Houghton PJ; Morton CL; Tucker C; Payne D; Favours E; Cole C; Gorlick R; Kolb EA; Zhang W; Lock R; Carol H; Tajbakhsh M; Reynolds CP; Maris JM; Courtright J; Keir ST; Friedman HS; Stopford C; Zeidner J; Wu J; Liu T; Billups CA; Khan J; Ansher S; Zhang J; Smith MA
Pediatr Blood Cancer; 2007 Dec; 49(7):928-40. PubMed ID: 17066459
[TBL] [Abstract][Full Text] [Related]
60. Development, characterization and therapy of a disseminated model of childhood neuroblastoma in SCID mice.
Thompson J; Guichard SM; Cheshire PJ; Richmond LB; Poquette CA; Ragsdale ST; Webber B; Lorsbach R; Danks MK; Houghton PJ
Cancer Chemother Pharmacol; 2001 Mar; 47(3):211-21. PubMed ID: 11320664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]